NCT05445180Recruiting
Investigating the Neural Correlates of Cognitive Function in Psychosis Patients and Non-Psychiatric Controls With Cannabis Use
Investigating the Neural Correlates of Cognitive Function Associated With Cannabis Abstinence in Psychosis Patients and Non-Psychiatric Controls With Cannabis Use
Source: ClinicalTrials.gov · Last updated 15 Sept 2026
Brief summary (registry, in English)
Cognitive impairment is well established in people with psychosis and is associated with cannabis use. The current study will investigate the neurobiological basis of cognitive change associated with 28-days of cannabis abstinence in people with psychosis and non-psychiatric controls with cannabis use. Participants will be randomized to a cannabis abstinent group or a non-abstinent control group and will undergo magnetic resonance imaging at baseline and following 28-days of abstinence. This study will help characterize the neuropathophysiological processes underlying cognitive dysfunction associated with cannabis use and its recovery which may guide the development of novel interventions for problematic cannabis use.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 134 (estimated)
- First submitted
- 18 May 2022
- Start date
- 21 Apr 2022
- Primary completion date
- 31 May 2027
- Lead sponsor
- Douglas Mental Health University Institute
- Diseases
- Schizophrenia
- NCT number
- NCT05445180
What you commit to
- Study type: Interventional
- Planned participants: 134
- From 21 Apr 2022 to the primary completion date, 31 May 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Taking psychotropic medication
Other illness
- Current medical diseases that requires hospitalization or regular monitoring
- DSM-5 Axis 1 diagnosis (other than CUD) (non-psychiatric controls only)
Other
- current SUD (other than CUD)
- MRI contraindications
- Positive urine screen for psychoactive substances other than cannabis, nicotine, or caffeine
- Current suicidal or homicidal ideation
- Head injury requiring hospitalization or loss of consciousness \> 5 minutes
- Being pregnant
Who the study is looking for
- Able to provide informed consent in English or French
- Heavy cannabis use (defined as weekly cannabis use for at six months) and/or DSM-5 diagnosis of CUD
- Have a Full-Scale IQ ≥ 75
- Meet DSM-5 criteria for a psychotic disorder (psychosis patient arm only)
- Be an outpatient receiving a stable dose of medication(s) for at least two months (psychosis patient arm only)
- Clinically stable (as measured by the PANSS-6, total score \<30) (psychosis patient arm only)
Age in the registry: 16 years to 80 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Douglas Mental Health University Institute Coordinator of this site? Confirm its status | Montreal | Canada | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.